预测局部晚期直肠癌中新辅助化学放射治疗的病理反应,采用两步特征选择和集体学习
Changshun Qian1,2, Shuxin Yang1, Yijing Chen2,3
1School of Information Engineering, Jiangxi University of Science and Technology, Ganzhou, 341000, China.
Scientific reports
|March 23, 2025
概括
这项研究确定了一个32基因对签名 (32-GPS) 作为一个强大的生物标志物,用于预测局部晚期直肠癌 (LARC) 患者的新辅助化学放射治疗 (nCRT) 反应. 开发的BoostForest模型显示出高精度,改善了LARC治疗反应预测.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 局部晚期直肠癌 (LARC) 患者对新辅助化学放射治疗 (nCRT) 的反应具有显著的变异性.
- 预测LARC中的nCRT反应是具有挑战性的,因为个体患者的差异和反应失衡.
- 准确预测治疗反应对于优化LARC管理至关重要.
研究的目的:
- 在LARC患者中确定nCRT反应的预测生物标志物.
- 开发一个集体学习模型来预测LARC中的nCRT响应.
- 通过改进反应预测,增强LARC的个性化治疗策略.
主要方法:
- 使用相对表达顺序 (REO) 识别稳定的基因对的两步特征选择方法.
- 使用MDFS,Boruta,MCFS和VSOLassoBag进行初步选,然后使用极端梯度增强 (XGBoost) 进行增量特征选择 (IFS).
- 开发BoostForest组合模型用于预测和SHAP用于可解释性.
主要成果:
- 一个32基因对签名 (32-GPS) 被确定为一个强大的预测生物标志物.
- 增强森林模型实现了高性能:AUPRC为0.983和准确度为0.988在测试组;AUPRC为0.785和准确度为0.898在验证队列.
- BoostForest的表现优于随机森林,支持矢量机 (SVM) 和XGBoost,32GPS显示出优越的预测能力,而不是其他基因组.
结论:
- 两步特征选择方法有效地确定了LARC中nCRT响应的强有力的预测生物标志物.
- 使用32GPS的BoostForest模型在预测治疗反应方面表现出卓越的性能.
- 这种方法有望改善LARC患者的个性化治疗选择和结果.
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...